- Home
- TNXP vs PROK Comparison
TNXP vs PROK Comparison
Compare TNXP & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- PROK
- Stock Information
- Founded
- TNXP 2007
- PROK 2015
- Country
- TNXP United States
- PROK United States
- Employees
- TNXP N/A
- PROK N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TNXP Health Care
- PROK Health Care
- Exchange
- TNXP Nasdaq
- PROK Nasdaq
- Market Cap
- TNXP 116.9M
- PROK 126.8M
- IPO Year
- TNXP N/A
- PROK N/A
- Fundamental
- Price
- TNXP $15.71
- PROK $0.79
- Analyst Decision
- TNXP Strong Buy
- PROK Buy
- Analyst Count
- TNXP 2
- PROK 4
- Target Price
- TNXP $585.00
- PROK $5.00
- AVG Volume (30 Days)
- TNXP 1.5M
- PROK 1.1M
- Earning Date
- TNXP 05-12-2025
- PROK 05-09-2025
- Dividend Yield
- TNXP N/A
- PROK N/A
- EPS Growth
- TNXP N/A
- PROK N/A
- EPS
- TNXP N/A
- PROK N/A
- Revenue
- TNXP $10,094,000.00
- PROK $76,000.00
- Revenue This Year
- TNXP $12.17
- PROK N/A
- Revenue Next Year
- TNXP $789.15
- PROK N/A
- P/E Ratio
- TNXP N/A
- PROK N/A
- Revenue Growth
- TNXP 29.94
- PROK N/A
- 52 Week Low
- TNXP $6.76
- PROK $0.46
- 52 Week High
- TNXP $672.00
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- TNXP 44.80
- PROK 45.47
- Support Level
- TNXP $15.23
- PROK $0.65
- Resistance Level
- TNXP $22.25
- PROK $1.18
- Average True Range (ATR)
- TNXP 2.36
- PROK 0.17
- MACD
- TNXP -0.54
- PROK 0.03
- Stochastic Oscillator
- TNXP 16.54
- PROK 45.97
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.